IPI-145

September 18, 2018

Verastem Launches Phase 1/2 Trial to Evaluate Duvelisib-Venclexta Combo in CLL/SLL Patients

News

Verastem Oncology has dosed the first patient in its Phase 1/2 trial testing a combination of duvelisib and Venclexta (venetoclax) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who failed ... Read more

April 12, 2018June 22, 2018

FDA Grants Priority Review to Duvelisib for Two Lymphoma Types

News

The U.S. Food and Drug Administration (FDA) will review an application requesting duvelisib’s full approval for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval for ... Read more